PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes:
“embecta, the world’s largest manufacturer of plastic insulin syringes, manufactures all of our syringes distributed worldwide at our facility in Holdrege, Nebraska,” said Shaun Curtis, SVP, Global Manufacturing & Supply Chain. “The safety notice issued by the FDA on November 30, 2023, only applies to plastic syringes made in China, and therefore has no impact on the ongoing production or sale of any embecta syringe products.”
“In the coming year, embecta will mark 100 years since our predecessors developed the world’s first syringe dedicated to insulin delivery, and we are proud of our rich heritage of quality, reliability, and innovation that we have earned in the years since. Our skilled workforce in Nebraska, with its unmatched expertise in high volume syringe manufacturing, is prepared to support any healthcare customers who may be affected by the FDA’s safety communication.”
About embecta
embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts:
Media | Investors | |
Christian Glazar | Pravesh Khandelwal | |
Sr. Director, Corporate Communications | VP, Head of Investor Relations | |
908-821-6922 | 551-264-6547 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. | Contact IR |
Last Trade: | US$10.73 |
Daily Change: | 0.13 1.23 |
Daily Volume: | 364,936 |
Market Cap: | US$627.060M |
February 06, 2025 September 03, 2024 August 09, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load